By Counterforce Health Team in Revcovi (elapegademase) —

Work With Your Doctor to Get Revcovi (Elapegademase) Approved by Cigna in North Carolina: Complete Provider Partnership Guide

Answer Box: Your Path to Cigna Approval in North Carolina

To get Revcovi (elapegademase) covered by Cigna in North Carolina for ADA-SCID, you need confirmed diagnosis documentation (genetic testing + ADA enzyme levels), specialist management by an immunologist, and a complete prior authorization showing failed/ineligible alternatives like bone marrow transplant. Start today by scheduling with your immunologist to gather diagnostic labs and prepare your medical necessity letter. If denied, North Carolina offers expedited external review through Smart NC within 72 hours for urgent cases.

Table of Contents

Set Your Goal: What Cigna Approval Requires

Cigna requires prior authorization for Revcovi and limits coverage to FDA-approved use in ADA-SCID under strict criteria. Based on Cigna's coverage policy, you'll need to demonstrate:

Core Requirements:

  • Confirmed ADA-SCID diagnosis (ICD-10 D81.31)
  • Genetic confirmation: Bi-allelic pathogenic ADA variants, OR
  • Enzymatic confirmation: Very low/absent ADA activity (<1% of normal)
  • Specialist requirement: Prescribing by or consultation with immunologist/hematologist
  • Treatment rationale: Documentation of why HSCT/gene therapy isn't immediately feasible

Your Partnership Strategy: Work with your immunologist to create a comprehensive submission that addresses each criterion with objective evidence. Your role is gathering documentation and ensuring clear communication; your provider's role is clinical interpretation and formal submission.

Note: Revcovi typically processes as a medical specialty drug through Cigna's Express Scripts/Accredo network, requiring both medical necessity and pharmacy benefit approval.

Visit Preparation: Building Your Clinical Case

Before Your Appointment:

1. Symptom Timeline Documentation Create a detailed log including:

  • Infection history: Types, frequency, hospitalizations, ICU stays
  • Growth/development: Weight curves, developmental milestones
  • Functional impact: Daily activities affected, school/work limitations
  • Emergency care: Date, facility, diagnosis, treatment for each episode

2. Treatment History Summary Document all previous therapies:

  • Prior medications: Names, doses, duration, reason for discontinuation
  • Hospitalizations: Dates, diagnoses, treatments, outcomes
  • Transplant evaluation: Status of HLA typing, donor search, eligibility assessment
  • Gene therapy: Availability, trial eligibility, barriers to access

3. Current Status Assessment Prepare to discuss:

  • Recent lab results: Complete blood count, lymphocyte subsets, immunoglobulins
  • Current medications: Including prophylactic antibiotics, IVIG/SCIG
  • Quality of life: Specific examples of how ADA-SCID affects daily functioning

Evidence Kit: Essential Documentation

Laboratory Evidence:

  • Genetic testing report showing bi-allelic ADA mutations
  • ADA enzyme activity results (erythrocyte ADA <1% of normal)
  • Immunologic workup: T/B/NK cell counts, T-cell function studies
  • Metabolite levels: dAXP (deoxyadenosine nucleotides) if available
  • Baseline labs: CBC, comprehensive metabolic panel, liver function

Clinical Documentation:

  • Newborn screening results (abnormal TREC if applicable)
  • Specialist consultation notes from immunology/hematology
  • Hospital discharge summaries for infection-related admissions
  • Imaging studies: Chest X-rays showing absent thymic shadow, lung changes

Treatment Planning:

  • HLA typing results for patient and family members
  • Transplant center evaluation (if completed)
  • Gene therapy screening documentation (eligibility, availability)

Counterforce Health helps patients organize this documentation into compelling, evidence-backed appeals that align with Cigna's specific requirements, turning complex medical records into targeted rebuttals of denial reasons.

Medical Necessity Letter Structure

Your immunologist should structure the letter to directly address Cigna's criteria:

Opening: Clear Diagnosis "I am writing to request prior authorization for Revcovi (elapegademase-lvlr) for [Patient Name], who has confirmed adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) based on [genetic testing showing bi-allelic ADA mutations] and [enzymatic confirmation of absent ADA activity]."

Clinical Rationale Section:

  • Disease severity: "ADA-SCID is a life-threatening primary immunodeficiency with high early mortality without effective treatment"
  • Treatment urgency: "Enzyme replacement therapy is standard of care to prevent life-threatening infections while definitive therapy is arranged"
  • Guideline support: Reference SCID management guidelines and FDA labeling

Alternatives Assessment:

  • HSCT status: "Patient lacks HLA-matched sibling donor; alternative donor transplant carries higher risk"
  • Gene therapy: "Currently available only through clinical trials; patient [meets/doesn't meet] eligibility criteria"
  • Risk of delay: "Without enzyme replacement, patient faces recurrent severe infections and potential death"

Monitoring Plan:

  • Dosing: Weight-based per FDA label (0.4 mg/kg/week maximum)
  • Lab monitoring: ADA activity, dAXP levels, lymphocyte counts per protocol
  • Clinical oversight: Regular immunology follow-up with response assessment

Peer-to-Peer Review Support

If Cigna requests a peer-to-peer review, support your provider with:

Availability Coordination:

  • Provide your schedule flexibility for urgent calls
  • Offer to join the call if your provider requests patient perspective
  • Ensure your provider has your current contact information

Case Summary Preparation: Create a one-page summary for your provider including:

  • Key diagnostic results: ADA mutation, enzyme levels, immune function
  • Clinical timeline: Diagnosis date, infections, hospitalizations
  • Treatment rationale: Why Revcovi is necessary now vs. waiting for alternatives
  • Response markers: How you'll measure treatment success

Talking Points for Your Provider:

  • Medical necessity: "This is FDA-approved therapy for confirmed ADA-SCID, not off-label use"
  • Standard of care: "Enzyme replacement is recommended by SCID guidelines while definitive therapy is planned"
  • Patient-specific factors: "This patient's clinical status requires immediate intervention to prevent life-threatening complications"
From our advocates: We've seen peer-to-peer reviews succeed when providers emphasize that ADA-SCID has a well-established treatment pathway, and Revcovi fits within accepted clinical guidelines rather than being an experimental approach. Clear documentation of the diagnosis and treatment timeline often resolves medical director concerns.

After Your Visit: Next Steps

Document Everything:

  • Visit summary: Key decisions, next appointments, action items
  • Prior authorization timeline: Expected submission date, follow-up schedule
  • Contact information: Direct numbers for your provider's PA coordinator
  • Reference numbers: Any case numbers or confirmation codes from submissions

Portal Communication: Use your provider's patient portal for:

  • Status updates: Regular check-ins on PA progress
  • Additional documentation: New lab results, insurance correspondence
  • Questions: Clarifications on treatment plan or insurance requirements

Insurance Coordination:

  • Member services: Call Cigna to confirm PA receipt and timeline
  • Benefits verification: Confirm coverage details and any patient responsibility
  • Appeal preparation: Understand your rights if the initial request is denied

Respectful Persistence: Following Up

Appropriate Cadence:

  • Week 1-2: Check PA submission status via portal or brief call
  • Week 3: If no response, contact both provider and insurance
  • Week 4+: Consider expedited review request if clinically urgent

Escalation Steps:

  1. Provider's PA coordinator for submission status
  2. Cigna case manager for review timeline
  3. Provider directly if delays threaten clinical stability
  4. Smart NC for external review preparation

Professional Communication:

  • Be specific: Reference dates, case numbers, and exact requests
  • Stay factual: Focus on medical necessity, not emotional appeals
  • Document interactions: Keep records of all calls and correspondence

North Carolina Appeals Process

North Carolina offers strong consumer protections through Smart NC, the state's external review program:

Internal Appeals (Cigna):

  • Timeline: 180 days from denial to file
  • Levels: Two internal review levels available
  • Expedited: 72 hours for urgent cases

External Review (Smart NC):

  • Eligibility: After internal appeals exhausted (or expedited pathway)
  • Timeline: 120 days from final internal denial
  • Process: Submit form to Smart NC, independent review organization assigned
  • Decision: Binding on insurer, 45 days standard (72 hours expedited)

Contact Smart NC:

  • Phone: 1-855-408-1212
  • Website: NCDOI Smart NC page
  • Services: Free advocacy, form assistance, medical record coordination

When dealing with rare diseases like ADA-SCID, Counterforce Health can help transform your clinical documentation into comprehensive appeals that address specific denial reasons with targeted, evidence-backed responses aligned to North Carolina's external review requirements.

FAQ

How long does Cigna prior authorization take in North Carolina? Standard PA decisions typically take 7-14 days when documentation is complete, potentially extending to 21-30 days for complex cases. Expedited reviews must be completed within 72 hours under federal requirements.

What if Revcovi is non-formulary on my Cigna plan? Request a formulary exception through Cigna's standard process, providing medical necessity documentation showing why formulary alternatives are inadequate for ADA-SCID.

Can I request an expedited appeal if denied? Yes, if delay would seriously jeopardize your health. Document specific clinical risks and request expedited review through both Cigna and Smart NC if needed.

Does step therapy apply to Revcovi for ADA-SCID? Typically no, since Revcovi is the primary FDA-approved enzyme replacement for ADA-SCID. However, insurers may require documentation that HSCT/gene therapy aren't immediately feasible.

What counts as medical necessity for Revcovi? Cigna's policy requires confirmed ADA-SCID diagnosis, specialist management, and clinical rationale for enzyme replacement versus other treatments.

How do I find an immunologist experienced with ADA-SCID in North Carolina? Contact Primary Immune Deficiency Foundation for specialist referrals, or ask major medical centers about their SCID programs and clinical immunology services.

What if my employer plan is self-funded and not subject to North Carolina external review? Check if your employer opted into North Carolina's system. If not, you may have federal ERISA appeal rights or access to independent review through your plan administrator.

Can Smart NC help me prepare my external review application? Yes, Smart NC staff provide free assistance with form completion, medical record gathering, and communication with insurers, though they cannot serve as your official representative.

Sources & Further Reading:

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Always consult with your healthcare provider and insurance company for guidance specific to your situation. Coverage policies and procedures may change; verify current requirements with your insurer and state regulators.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.